Home › NCT04343365

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients

Who can join

All ages · All sexes

Inclusion Criteria:

* Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
* Participant must have a life expectancy greater than 3 months
* Participant must have an ECOG performance status 0-2
* Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
* Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

Exclusion Criteria:

* None

About the study

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

What is being tested

• Evolutionary Tumor Board (ETB) (other)

Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Participants: 35 · Started: May 5, 2020

Contact the study team

• Sara Donadelli · Phone: 813-745-8111

Official record on ClinicalTrials.gov — NCT04343365

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.